Skip to main content

Advertisement

SpringerLink
Log in

IVF for fertility preservation in breast cancer patients—efficacy and safety issues

  • Fertility Preservation
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Background

Potential risks on future fertility have become a dominant issue in consultation and management of newly diagnosed young cancer patients. Several fertility preservation strategies are currently available. Of those, ovarian stimulation followed by IVF and embryo cryopreservation is the most established one and is especially applicable in reproductive aged breast cancer patients.

Aim

The aim of this study is to provide a comprehensive review on ovarian stimulation and IVF for fertility preservation in newly diagnosed breast cancer patients.

Methods

Review of relevant literature is available through PubMed and Google scholar.

Results

The use of IVF for fertility preservation in breast cancer patients raises dilemmas regarding efficacy and safety of controlled ovarian stimulation. Among these are the suggested role of malignancy and BRCA mutation in reducing ovarian response to stimulation, strategies designated to protect against hyper-estrogenic state associated with stimulation (co-treatment with tamoxifen or letrozole), and possible adjustments to accommodate oncologic-related time constraints.

Conclusion

Ovarian stimulation followed by IVF forms an important fertility preservation strategy for newly diagnosed young breast cancer patients, though live born rates following thawed embryo transfer in these patients are still lacking. Recent advances in controlled ovarian stimulation protocols provide practical options for some of the challenges that breast cancer patients present.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013;309(8):800–5.

    Article  CAS  PubMed  Google Scholar 

  2. Merlo DF et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. Breast Cancer Res Treat. 2012;134(1):363–70.

    Article  CAS  PubMed  Google Scholar 

  3. Azim Jr HA et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73–9.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Anders CK et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol. 2011;29(1):e18–20.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Anders CK et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–30.

    Article  PubMed  Google Scholar 

  6. Cardoso F et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48(18):3355–77.

    Article  PubMed  Google Scholar 

  7. Meirow D et al. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010;53(4):727–39.

    Article  PubMed  Google Scholar 

  8. Demeestere I et al. Multiple approaches for individualized fertility protective therapy in cancer patients. Obstet Gynecol Int. 2012;2012:961232.

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Lee SJ et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31.

    Article  PubMed  Google Scholar 

  10. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535–43.

    Article  CAS  PubMed  Google Scholar 

  11. Okanami Y et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182–8.

    Article  PubMed  Google Scholar 

  12. Letourneau JM et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Schover LR et al. Having children after cancer. A pilot survey of survivors’ attitudes and experiences. Cancer. 1999;86(4):697–709.

    Article  CAS  PubMed  Google Scholar 

  14. Loren AW et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.

    Article  PubMed  Google Scholar 

  15. Partridge AH et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209–20.

    Article  PubMed  Google Scholar 

  16. Peccatori FA et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi160–70.

    Article  PubMed  Google Scholar 

  17. Moore HC et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32.

    Article  CAS  PubMed  Google Scholar 

  18. Courbiere B et al. Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study. Hum Reprod. 2013;28(9):2381–8.

    Article  CAS  PubMed  Google Scholar 

  19. Johnson LN et al. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod Biomed Online. 2013;26(4):337–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Michaan N et al. Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients. Eur J Obstet Gynecol Reprod Biol. 2010;149(2):175–7.

    Article  PubMed  Google Scholar 

  21. Robertson AD, Missmer SA, Ginsburg ES. Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril. 2011;95(2):588–91.

    Article  PubMed  Google Scholar 

  22. Cardozo ER et al. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience. J Assist Reprod Genet. 2015;32(4):587–96.

    Article  PubMed  Google Scholar 

  23. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril. 2014;101(5):1237–43.

  24. Cobo A et al. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril. 2013;99(6):1485–95.

    Article  PubMed  Google Scholar 

  25. Cobo A et al. Obstetric and perinatal outcome of babies born from vitrified oocytes. Fertil Steril. 2014;102(4):1006–15.e4.

    Article  PubMed  Google Scholar 

  26. Potdar N, Gelbaya TA, Nardo LG. Oocyte vitrification in the 21st century and post-warming fertility outcomes: a systematic review and meta-analysis. Reprod Biomed Online. 2014;29(2):159–76.

    Article  PubMed  Google Scholar 

  27. Garcia-Velasco JA et al. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99(7):1994–9.

    Article  PubMed  Google Scholar 

  28. Kim SS, Klemp J, Fabian C. Breast cancer and fertility preservation. Fertil Steril. 2011;95(5):1535–43.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Martinez M et al. Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer. Reprod Biomed Online. 2014;29(6):722–8.

    Article  PubMed  Google Scholar 

  30. Porcu E et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online. 2008;17(2):265–7.

    Article  CAS  PubMed  Google Scholar 

  31. Sanchez-Serrano M et al. Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil Steril. 2010;93(1):268.e11–3.

    Article  Google Scholar 

  32. Yang D et al. Live birth after the transfer of human embryos developed from cryopreserved oocytes harvested before cancer treatment. Fertil Steril. 2007;87(6):1469.e1–4.

    Article  Google Scholar 

  33. Chung K et al. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril. 2013;99(6):1534–42.

    Article  PubMed  Google Scholar 

  34. Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr. 2005;34:21–5.

    Article  CAS  PubMed  Google Scholar 

  35. Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod Biomed Online. 2004;9(6):673–9.

    Article  PubMed  Google Scholar 

  36. Knopman JM et al. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril. 2009;91(4 Suppl):1476–8.

    Article  PubMed  Google Scholar 

  37. Quintero RB et al. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010;93(3):865–8.

    Article  CAS  PubMed  Google Scholar 

  38. Klock SC, Zhang JX, Kazer RR. Fertility preservation for female cancer patients: early clinical experience. Fertil Steril. 2010;94(1):149–55.

    Article  PubMed  Google Scholar 

  39. Domingo J et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97(4):930–4.

    Article  PubMed  Google Scholar 

  40. Engmann L et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91.

    Article  CAS  PubMed  Google Scholar 

  41. Pal T et al. Fertility in women with BRCA mutations: a case–control study. Fertil Steril. 2010;93(6):1805–8.

    Article  CAS  PubMed  Google Scholar 

  42. Smith KR et al. Effects of BRCA1 and BRCA2 mutations on female fertility. Proc Biol Sci. 2012;279(1732):1389–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Finch A et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–8.

    Article  CAS  PubMed  Google Scholar 

  44. Collins IM et al. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. J Clin Oncol. 2013;31(31):3920–5.

    Article  PubMed  Google Scholar 

  45. Valentini A et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013;31(31):3914–9.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Michaelson-Cohen R et al. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer. 2014;24(2):233–7.

    Article  PubMed  Google Scholar 

  47. van Tilborg TC, Broekmans FJM, Schrijver LH, Mooij TM, Pijpe A, Oosterwijk JC, Verhoef S, Gómez Garcia EB, van Zelst-Stams WAG, Adank MA, van Asperen CJ, van Doorn HC, van Os TAM, Rookus MA, Ausems MGEM. BRCA1/2 mutation carriers do not have earlier natural menopause compared to proven non-carriers: report from the Dutch hereditary breast and ovarian cancer study group (HEBON). Munich, Germany; 2014.

  48. Verpoest W, Elsen E, Mackens S, De Rycke M, Bonduelle M, Van de Velde H, Blockeel C, De Vos M, Polyzos N, Tournaye H. Ovarian response in BRCA1 carriers: a case–control study, in European Soc of Hum Reprod (ESHRE). Munich, Germany; 2014.

  49. Rzepka-Gorska I et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat. 2006;100(1):59–63.

    Article  CAS  PubMed  Google Scholar 

  50. Oktay K et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Lin WT et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Titus S et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21.

    Article  PubMed  Google Scholar 

  53. Wang ET et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723–8.

    Article  CAS  PubMed  Google Scholar 

  54. Oktay K et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90–5.

    Article  CAS  PubMed  Google Scholar 

  55. Oktay K et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53.

    Article  CAS  PubMed  Google Scholar 

  56. Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online. 2010;20(6):783–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Oktay K et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885–90.

    Article  CAS  PubMed  Google Scholar 

  58. Kim JH et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci. 2015;30(3):290–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Revelli A et al. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol. 2013;29(11):993–6.

    Article  CAS  PubMed  Google Scholar 

  60. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.

    Article  CAS  PubMed  Google Scholar 

  61. Meirow D, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility—preservation treatment strategies. Fertil Steril. 2014.

  62. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

  63. Davies C et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

    Article  CAS  PubMed  Google Scholar 

  64. Goldhirsch A et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Senkus E et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi7–23.

    Article  PubMed  Google Scholar 

  66. Cold S et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer. 2005;93(6):627–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Lohrisch C et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24(30):4888–94.

    Article  PubMed  Google Scholar 

  68. Turan V et al. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril. 2013;100(6):1681–5.e1.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003;80(1):116–22.

    Article  PubMed  Google Scholar 

  70. Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012;18(1):73–91.

    Article  PubMed  Google Scholar 

  71. Bentov Y et al. An ongoing pregnancy from two waves of follicles developing during a long follicular phase of the same cycle. Fertil Steril. 2010;94(1):350.e8–11.

    Article  Google Scholar 

  72. Anderson RA, Kinniburgh D, Baird DT. Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment. Hum Reprod. 1999;14(10):2665–8.

    Article  CAS  PubMed  Google Scholar 

  73. Bedoschi GM et al. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010;27(8):491–4.

    Article  PubMed Central  PubMed  Google Scholar 

  74. von Wolff M et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009;92(4):1360–5.

    Article  Google Scholar 

  75. Cakmak H et al. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.

    Article  PubMed  Google Scholar 

  76. Nayak SR, Wakim AN. Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. Fertil Steril. 2011;96(1):e51–4.

    Article  PubMed  Google Scholar 

  77. Checa MA et al. Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial. Int J Womens Health. 2015;7:219–25.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Kuang Y et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Source of funding

None.

Author information

Authors and Affiliations

  1. IVF Unit, Division of Obstetrics and Gynecology, Fertility Preservation Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel

    M. Shapira, H. Raanani & D. Meirow

  2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    M. Shapira, H. Raanani & D. Meirow

Authors
  1. M. Shapira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Raanani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Meirow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Meirow.

Additional information

Capsule A comprehensive review on ovarian stimulation for fertility preservation in newly diagnosed breast cancer patients, along with a preliminary presentation of our reassuring experience with BRCA mutation carriers undergoing this procedure.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shapira, M., Raanani, H. & Meirow, D. IVF for fertility preservation in breast cancer patients—efficacy and safety issues. J Assist Reprod Genet 32, 1171–1178 (2015). https://doi.org/10.1007/s10815-015-0519-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-015-0519-x

Keywords

Search

Navigation